The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure

Prior treatment

• Urgent surgical intervention.
• Presently engaged in concurrent participation in additional clinical trials.

Other illness

• Patients who exhibit contraindications to oropharyngeal airway ventilation, such as coagulation disorders, a predisposition to oral and nasal bleeding, mucosal damage, or anatomical constraints impeding oropharyngeal channel placement.
• Severe cardiac insufficiency, defined as a maximal exercise capacity of less than 4 metabolic equivalents (METs).
• Profound renal insufficiency necessitating preoperative dialysis.
• Patients diagnosed with chronic obstructive pulmonary disease (COPD) or those presently experiencing other acute and chronic pulmonary conditions necessitating prolonged or intermittent oxygen therapy.
• Upper respiratory tract infections, encompassing the oral, nasal, and pharyngeal regions.
• Hypersensitivity reactions to sedatives like propofol or medical equipment such as adhesive tape.
• Patients with a documented history of substance abuse, specifically drugs and/or alcohol, within the two years preceding the commencement of the screening period. Substance abuse in this context is defined as consuming more than three standard alcoholic beverages daily, roughly equivalent to 10g of alcohol or 50g of Chinese Baijiu.
• Patients with a history of mental and neurological disorders, including but not limited to depression, severe central nervous system depression, Parkinson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease, and myasthenia gravis.

Other

• A confirmed severe liver dysfunction.
• Elevated intracranial pressure.
• Fever, defined as a core body temperature exceeding 37.5 degrees Celsius.
• Pregnancy or lactation.
• Polytrauma.
• Peripheral oxygen saturation (SpO2) levels below 95% while breathing room air preoperatively.
• BMI\<18.5 or BMI\>30.
• Patients considered ineligible by researchers for inclusion in this clinical trial.

• Age 18≤ Age ≤60.
• Patients undergoing gastroendoscopy and/or colonoscopy procedure.
• Patients have signed the informed consent form.
• The ASA classification ranges from I to II.
• The estimated duration of the procedure does not exceed 45 minutes.